Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Ipamorelin: mechanism of action

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a ghrelin receptor (GHSR-1a) agonist; this page sets out its receptor pharmacology and the models in which its activity has been studied.

peptides-pro Editorial

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) and a selective agonist of the growth hormone secretagogue receptor 1a (GHSR-1a), the receptor also targeted by the endogenous ligand ghrelin. It is catalogued among the growth hormone secretagogues — alongside GHRP-2, GHRP-6 and hexarelin — in reviews of peptides marketed as research compounds and intended to modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis [3]. The evidence block supplied for this page does not give a sequence, molecular formula or molecular weight for the compound, so none is stated here.

The work on this compound centres on the GHSR-1a receptor and, downstream of it, the GH-IGF-1 axis [3].

Research Studies

Ipamorelin and GHSR-1a agonism in the GH-IGF-1 axis

Ipamorelin is classified as a growth hormone secretagogue, a group defined by its interaction with the ghrelin receptor rather than by any single downstream effect. Reviews of performance-enhancing peptides that modulate the GH-IGF-1 axis list ipamorelin within this class, together with GHRP-2, GHRP-6 and hexarelin, and distinguish the class from the GHRH analogues (sermorelin, tesamorelin, CJC-1295 with and without DAC), from the GH fragment AOD9604 (hGH 176-191), and from IGF-1 analogues [3]. That classification places the compound's primary mechanism at the receptor level, with somatotropic signalling as the axis under study.

Ipamorelin and post-operative gastrointestinal recovery in surgical patients

A registered clinical study has examined post-operative administration of ipamorelin in patients who had undergone partial small and/or large bowel resection, with the stated expectation that treatment would reduce the time to recovery of gastrointestinal function in that population [1]. The same research programme includes a separate registered study whose purpose was to determine whether ipamorelin is safe and effective in the management of post-operative ileus [2]. Both are recorded as clinical investigations in surgical patients; the evidence block reports the objectives of those studies rather than their results.

Registered studyPopulationStated objective
NCT01280344 [1]Patients after partial small and/or large bowel resectionReduce time to recovery of GI function
NCT00672074 [2]Patients with post-operative ileusDetermine safety and efficacy in management of post-operative ileus

Ipamorelin and cisplatin-induced weight loss in ferrets

In an animal study, the GHSR-1a agonists anamorelin and ipamorelin were investigated for their capacity to alleviate weight loss and the inhibition of feeding seen during the acute and delayed phases of cisplatin-induced emesis in ferrets. The same work examined whether anamorelin could inhibit electrically field-stimulated contractions of isolated tissue, and reported that anamorelin also showed anti-emetic effects through a central mechanism [9]. This is an animal model, and the findings are attributed to the ferret.

Ipamorelin and the hypothalamic-pituitary-testicular axis in a cichlid fish

Ipamorelin acetate, described as a ghrelin agonist, was administered to the tilapia Oreochromis mossambicus in a study designed to examine its impact on the reproductive axis of that species. The work is framed around ghrelin as a peptide found in brain and gut and predicted to contribute to the control of several physiological systems in fish [10]. This is a non-mammalian animal model, and the observations belong to that species.

Ipamorelin and peptide purity in the consumer market

Ipamorelin appears in the wider literature not only as a pharmacological subject but as a marketed product. An evaluation of research-grade peptides sold directly to consumers used a large, publicly available independent testing dataset to assess purity, measured abundance and endotoxin burden, and to compare cost against compounded and FDA-approved alternatives; the dataset covered thousands of peptide preparations [4]. The framing of that work is that peptides are a rapidly expanding drug class with a parallel, largely unregulated gray market selling preparations directly to consumers for self-administration, and that patients self-administer such compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss and athletic performance enhancement [4].

Ipamorelin and the regulatory status of unapproved peptides

Reviews of peptide use in sports medicine place unapproved compounds in a separate category from peptide drugs that have completed a rigorous approval process evaluating both safety and efficacy, describing a parallel gray market operating largely outside regulatory oversight [6][7]. Ipamorelin is named among the prominent approved and unapproved peptides marketed direct to patients in that literature [6][7]. Related reviews note that injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair and performance enhancement, while clinical adoption has outpaced high-quality evidence and regulatory consensus [12], and that peptide supplements are often perceived as low risk despite the absence of efficacy or safety data [11].

Ipamorelin and the therapeutic peptide literature in aging and gerontology

Ipamorelin sits within a broader therapeutic peptide literature that targets hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline. A narrative review of peptide therapeutics in gerontological medicine surveyed mechanisms, clinical applications, evidence base and safety profiles, drawing on PubMed, Scopus and regulatory databases including the FDA and WADA [5]. That review is a general treatment of the peptide class rather than a study of ipamorelin specifically.

Ipamorelin and the limits of the current evidence base

Across the material summarised here, the mechanistic claim that is best supported is the receptor-level one: ipamorelin is a GHSR-1a agonist and a growth hormone secretagogue [3]. The clinical material consists of registered studies in surgical patients whose reported objectives concern gastrointestinal recovery and post-operative ileus [1][2]. The remaining primary findings come from animal models — ferrets [9] and a cichlid fish [10] — and from market and regulatory analyses of peptides sold to consumers [4][6][7]. Reviews of the field state directly that clinical adoption of injectable peptides has outpaced high-quality evidence [12] and that efficacy and safety data are absent for much of the supplement market [11]. No human dose, pharmacokinetic parameter or efficacy outcome for ipamorelin is supplied by the evidence block, and none is asserted here.

If you are reading this for personal health reasons

The material described on this page is sold for laboratory research use only, and we do not provide dosing or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing here is a recommendation, a protocol, or a substitute for professional medical advice.

Sources

WhatsApp